Kazia Therapeutics Ltd Sponsored ADR Stock

$5.49

4.69% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

US48669G1058

Symbol

KZIA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Kazia Therapeutics Ltd Sponsored ADR Stock price

$5.49

-50.61 90.21% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

-0.27 4.69%

ISIN

US48669G1058

Symbol

KZIA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$18.27m
Enterprise Value	$17.58m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	11.57
P/S ratio (TTM) P/S ratio	12.02
P/B ratio (TTM) P/B ratio	negative
Revenue (TTM) Revenue	$1.52m
EBIT (operating result TTM) EBIT	$-18.80m
Free Cash Flow (TTM) Free Cash Flow	$-5.54m
EPS (TTM) EPS	$-6.66
Short interest	1.68%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Kazia Therapeutics Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Kazia Therapeutics Ltd Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Kazia Therapeutics Ltd Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Kazia Therapeutics Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	1.52 1.52	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	7.68 7.68	70% 70% 505%
- Research and Development Expense	10 10	11% 11% 670%
EBITDA	-18 -18	17% 17% -1,156%
- Depreciation and Amortization	1.22 1.22	3% 3% 80%
EBIT (Operating Income) EBIT	-19 -19	16% 16% -1,237%
Net Profit	-18 -18	28% 28% -1,156%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kazia Therapeutics Ltd Sponsored ADR Stock News

Neutral

PRNewsWire

●

22 days ago

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM) Company updates to corporate presentation and participation in upcoming medical meetings SYDNEY , Nov. 4, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration ...

Neutral

PRNewsWire

●

about 2 months ago

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR) Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favorably to historical response rates for whole brain radiation therapy alone SYDNEY , Oct. 2, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development comp...

Neutral

PRNewsWire

●

2 months ago

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

SYDNEY , Sept. 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the ...

More Kazia Therapeutics Ltd Sponsored ADR News

Company Profile

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Head office	Australia
CEO	John Friend
Founded	1994
Website	www.kaziatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now